• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

    8/1/25 1:29:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care
    Get the next $OSRH alert in real time by email

    BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a  global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time).

    OSR Holdings logo (PRNewsfoto/OSR Holdings)

    The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting.

    Event Details

    Date: Wednesday, August 6, 2025

    Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KST

    Location: Virtual (livestream access)

    Registration: Opens Monday, August 4 at www.osr-holdings.com/events

    Replay: Available after the event on the OSR Holdings Investor Relations website.

    Agenda Highlights

    • Corporate overview and strategic vision
    • Subsidiary and R&D pipeline updates:
      • Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies
      • Darnatein: DRT101 – a potent DMOAD candidate
      • Woori IO acquisition: The opportunity for noninvasive CGM
    • Equity Line of Credit (ELOC) financing strategy
    • Blockchain & Tokenization strategy
    • Live Q&A with management

    "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."



    Featured Speakers:

    • Mr. Peter Hwang – Chief Executive Officer
    • Dr. Constance Höfer – Chief Scientific Officer
    • Mr. Tim Smith – Global Investor Relations

    About OSR Holdings, Inc.

    OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit www.OSR‑Holdings.com. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-to-host-virtual-investor-event-providing-key-corporate-updates-and-strategic-direction-on-august-6-2025-302519839.html

    SOURCE OSR Holdings

    Get the next $OSRH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSRH
    SEC Filings

    View All

    SEC Form 10-Q filed by OSR Holdings Inc.

    10-Q - OSR Holdings, Inc. (0001840425) (Filer)

    11/12/25 2:02:36 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    10/16/25 11:10:18 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by OSR Holdings Inc.

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    9/23/25 8:40:55 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

    BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm is a Swiss-German biotech company developing oral T-cell immunotherapies for cancer and a subsidiary of OSR Holdings, Inc. Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the co

    11/14/25 11:10:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

    BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration with Korea University Guro Hospital. The study, which took place from May 9 to September 12, 2023, evaluated the performance of the Glucheck blood glucose measurement system and validated its accuracy, stability, and usability across a representative participant group. Although the Clinical Study Report (CSR) for this exploratory trial was completed in 2023, Woori IO, then a

    11/6/25 8:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

    BELLEVUE, Wash., Oct. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

    10/14/25 8:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fierz Reto Kaspar

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    10/24/25 12:58:23 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Leadership Updates

    Live Leadership Updates

    View All

    OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

    BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm is a Swiss-German biotech company developing oral T-cell immunotherapies for cancer and a subsidiary of OSR Holdings, Inc. Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the co

    11/14/25 11:10:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

    BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

    7/15/25 7:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

    BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a

    3/25/25 7:00:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care